Shares of boohoo Group PLC, now Debenhams Group, held steady after its half-year update. Broker Shore Capital maintained a 'buy' rating and raised its price target to 35p, suggesting nearly 50% upside from the current 24p. The broker highlighted accelerating sales, improved gross margins, and growth in the marketplace model as signs of recovery progress. Recent asset sales, including a £90 million warehouse and the Nasty Gal brand, support a shift to a capital-light model, improving profit forecasts and turning net debt into net cash. However, Shore Capital cautioned that the clothing market remains challenging in the near term, and long-term growth depends on boohoo's ability to sustain momentum across the group.
Shares of boohoo Group PLC, now Debenhams Group, provide context for consumer cyclical stocks. For readers following this sector, here is Pluang's market snapshot as of Sep 17, 2026 23:41 WIB: out of 105 US consumer cyclical stocks, 70 rose and 35 fell. Tesla (TSLA) traded at USD 367.65 with a 1-day change of +2.67%, while Gap (GAP) and Target (TGT) both saw 100% buy order activity with prices of USD 20.70 and USD 158.71 respectively.
KB Home is set to report its Q3 2026 earnings on September 22, with analysts projecting a 45.3% drop in earnings per share to around $0.89 and a 20.2% decline in revenue to about $1.30 billion compared to last year. The consensus EPS estimate has rec...
An investment of $10,000 in Nebius when it resumed trading in 2024 has grown significantly to approximately $105,000 by 2026. This remarkable increase highlights Nebius's strong market performance over the two-year period. Investors who bought in at ...
W.P. Carey expects to invest over $1.9 billion in 2026, reflecting robust growth in its net lease property portfolio. Despite a slight reduction in its price target by Scotiabank to $76, the stock still shows potential upside from current levels. The...
Micron Technology is investing $10 billion over the next decade to establish Micron Research Labs, a new division focused on future memory architectures and advanced semiconductor manufacturing. The company shows strong financial health with a low de...
Impact Biomedical Inc. will conduct a 1-for-12.62 reverse stock split on September 23, 2026, consolidating shares without changing shareholder value. This move facilitates its planned merger with Zoar Ltd., with a Form F-4 registration filed with the...
